mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?

BACKGROUND: COVID-19 vaccines are recommended for people with multiple sclerosis (pwMS). Adequate humoral responses are obtained in pwMS receiving disease-modifying therapies (DMTs) after vaccination, with the exception of those receiving B-cell-depleting therapies and non-selective S1P modulators....

Descripción completa

Detalles Bibliográficos
Autores principales: Tütüncü, Melih, Demir, Serkan, Arslan, Gökhan, Dinç, Öykü, Şen, Sedat, Gündüz, Tuncay, Uzunköprü, Cihat, Gümüş, Haluk, Tütüncü, Mesude, Akçin, Rüveyda, Özakbaş, Serkan, Köseoğlu, Mesrure, Bünül, Sena Destan, Gezen, Ozan, Tezer, Damla Çetinkaya, Baba, Cavid, Özen, Pınar Acar, Koç, Rabia, Elverdi, Tuğrul, Uygunoğlu, Uğur, Kürtüncü, Murat, Beckmann, Yeşim, Doğan, İpek Güngör, Turan, Ömer Faruk, Boz, Cavit, Terzi, Murat, Tuncer, Asli, Saip, Sabahattin, Karabudak, Rana, Kocazeybek, Bekir, Efendi, Hüsnü, Bilge, Uğur, Siva, Aksel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170898/
https://www.ncbi.nlm.nih.gov/pubmed/37247488
http://dx.doi.org/10.1016/j.msard.2023.104761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170898/
https://www.ncbi.nlm.nih.gov/pubmed/37247488
http://dx.doi.org/10.1016/j.msard.2023.104761

Ejemplares similares